GAITHERSBURG, Md.--(BUSINESS WIRE)--Feb. 9, 2006--GenVec, Inc. (Nasdaq:GNVC) announced today that it has received initial funding of $300,000 to begin preliminary vector development with the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health, in preparation for the manufacture of clinical grade adenovector-based influenza vaccines. This initial seasonal and pandemic flu vaccine research effort was agreed to through an extension of the $50 million subcontract issued and managed by SAIC-Frederick under which GenVec has been working to develop and manufacture adenovector-based HIV vaccines in collaboration with the VRC.
